These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Clinical studies on the fibrinolytic action of pentosan polysulfate]. Vinazzer H. Folia Haematol Int Mag Klin Morphol Blutforsch; 1986 Dec 17; 113(1-2):272-7. PubMed ID: 2427410 [Abstract] [Full Text] [Related]
5. Metabolism of sodium pentosan polysulphate in man measured by a new competitive binding assay for sulphated polysaccharides--comparison with effects upon anticoagulant activity, lipolysis and platelet alpha-granule proteins. MacGregor IR, Dawes J, Pepper DS, Prowse CV, Stocks J. Thromb Haemost; 1985 Jun 24; 53(3):411-4. PubMed ID: 2413564 [Abstract] [Full Text] [Related]
6. A comparison of pentosan polysulphate and heparin. II: Effects of subcutaneous injection. Fischer AM, Merton RE, Marsh NA, Williams S, Gaffney PJ, Barrowcliffe TW, Thomas DP. Thromb Haemost; 1982 Apr 30; 47(2):109-13. PubMed ID: 6179183 [Abstract] [Full Text] [Related]
7. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers. Siegbahn A, Ruusuvaara L. Thromb Haemost; 1988 Dec 22; 60(3):361-4. PubMed ID: 3149043 [Abstract] [Full Text] [Related]
10. Metabolism of sodium pentosan polysulphate in man--catabolism of iodinated derivatives. MacGregor IR, Dawes J, Paton L, Pepper DS, Prowse CV, Smith M. Thromb Haemost; 1984 Jul 29; 51(3):321-5. PubMed ID: 6208629 [Abstract] [Full Text] [Related]
11. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways. Munkvad S. Dan Med Bull; 1993 Sep 29; 40(4):383-408. PubMed ID: 8222763 [Abstract] [Full Text] [Related]
14. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. Meijers JC, Middeldorp S, Tekelenburg W, van den Ende AE, Tans G, Prins MH, Rosing J, Büller HR, Bouma BN. Thromb Haemost; 2000 Jul 29; 84(1):9-14. PubMed ID: 10928462 [Abstract] [Full Text] [Related]
15. The interaction of pentosan polysulphate (SP54) with human neutrophil elastase and connective tissue matrix components. Andrews JL, Ghosh P, Lentini A, Ternai B. Chem Biol Interact; 1983 Nov 29; 47(2):157-73. PubMed ID: 6197196 [Abstract] [Full Text] [Related]
16. Identification of heparin cofactor II as the principal plasma cofactor for the antithrombin activity of pentosan polysulphate (SP54). Scully MF, Kakkar VV. Thromb Res; 1984 Oct 15; 36(2):187-94. PubMed ID: 6209821 [Abstract] [Full Text] [Related]
17. Release of plasminogen activator by pentosan polysulphate. Klöcking HP, Markwardt F. Thromb Res; 1986 Mar 01; 41(5):739-44. PubMed ID: 2421436 [No Abstract] [Full Text] [Related]
18. Heparin and fibrinolysis--comparison of subcutaneous administration of unfractionated and low molecular weight heparin. Eriksson E, Wollter IM, Christenson B, Stigendal L, Risberg B. Thromb Haemost; 1988 Apr 08; 59(2):284-8. PubMed ID: 2838926 [Abstract] [Full Text] [Related]
19. Influence of anaesthetics on the fibrinolytic activity in minipigs. Klöcking HP, Sedlarik K. Folia Haematol Int Mag Klin Morphol Blutforsch; 1988 Apr 08; 115(1-2):132-5. PubMed ID: 2459007 [Abstract] [Full Text] [Related]
20. Tolerance and biological activity of pentosan polysulfate after intramuscular or subcutaneous administration for ten days in human volunteers. Sié P, Albarede JL, Robert M, Bouloux C, Lansen J, Chigot C, Correll S, Thouvenot JP, Boneu B. Thromb Haemost; 1986 Feb 28; 55(1):86-9. PubMed ID: 2422778 [Abstract] [Full Text] [Related] Page: [Next] [New Search]